Skip to content

ImmunityBio, Inc. IBRX Accrued Compensation

Accrued Compensation at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$6.76B-4.1%
Exelixis logo
ExelixisEXEL
$87.51M-2.5%
TG Therapeutics logo
TG TherapeuticsTGTX
$18.66M+263%
Spyre Therapeutics, Inc. logo
Spyre Therapeutics, Inc.SYRE

Other financials

Income statement

See full
Revenue$44.2M+168%
Gross profit$44.0M+167%
Operating income-$69.8M-8.3%
Net income-$632.8M-388%
EPS (diluted)-$0.62-313%

Balance sheet

See full
Cash & equivalents$205.2M+238%
Total debt$445.4M+32.2%
Total equity-$870.0M-47.1%
Total assets$646.6M+113%

Cash flow

See full
Operating cash flow-$75.4M+12.3%
CapEx$1.8M+58.4%
Free cash flow-$77.1M+11.4%

Valuation

See full
Market cap$7.71B+208%
Enterprise value$7.95B+187%
P/S54.7×-25.4×

Profitability

See full
Gross margin99.3%-0.5pp
Operating margin-185.4%-83.3pp
Net margin-606.2%-212pp
FCF margin-212%-95.8pp

Returns & leverage

See full
Return on equity-119.3%
Debt / equity0.1×
Current ratio6.7×+4.4×

Where this comes from

Reported directly by ImmunityBio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AccruedSalariesCurrent.

The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about ImmunityBio, Inc.'s accrued compensation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ImmunityBio, Inc.'s accrued compensation?
ImmunityBio, Inc. (IBRX) reported accrued compensation of $7.33M in Q1 2026.
How has ImmunityBio, Inc.'s accrued compensation changed year-over-year?
ImmunityBio, Inc.'s accrued compensation increased by 25.1% year-over-year, from $5.86M to $7.33M.
What is the long-term trend for ImmunityBio, Inc.'s accrued compensation?
Over 5 years (2020 to 2025), ImmunityBio, Inc.'s accrued compensation has grown at a 8.0% compound annual growth rate (CAGR), from $3.89M to $5.72M.